Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Editas Medicine $231 million stock offering
We advised the joint book-running managers in connection with the equity offering
Innovent Biologics HK$4.73 billion placement of shares
We advised the joint placing agents in connection with the equity offering
IDEAYA Biosciences $90 million at-the-market offering
We advised the sales agent on the SEC-registered equity offering
American Well $356.8 million secondary offering
We advised Amwell on the stock offering
Affimed $115 million offering of shares
We advised the underwriters on the public equity offering
REGENXBIO $230.3 million stock offering
We advised the underwriters on a public equity offering
Generation Bio $225.4 million stock offering
We advised the underwriters on the public equity offering
NeoGenomics $230 million stock and $345 million convertible notes offerings
We advised the joint book-running managers on the public offerings of stock and convertible notes
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
NGM Biopharmaceuticals $125 million follow-on offering
We advised the joint book-running managers on the public equity offering